The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...
The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Enrollment insights in the synchronous mRCC population: An update from the ongoing ADAPT* phase 3 study experience. Background: Pazopanib is an oral, selective, multikinase inhibitor of VEGF receptors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results